

Day 3 - 3 December 2010

MORNING PLENARY SESSIONS

08:30 - 10:30 - Finding the Right Level

- 08:30 - 08:40 - Margarete Brudny-Kloeppel (Bayer Schering Pharma AG, on behalf of EBF) p. 28
Introduction
- 08:40 - 09:10 - Fabio Garofolo (Algorithme Pharma Inc.) p. 28
When and How Much do Anomalous Results Need to be Investigated?
- 09:10 - 09:40 - Silke Lüttke (Boehringer-Ingelheim, on behalf of EBF) p. 29
Handling of Anomalous Results in Europe – Feedback from EBF Survey
- 09:40 - 10:10 - EBF Speaker
Case studies of anomalous results and their resolution
- 10:10 - 10:30 - Panel Discussion
- 10:30 - 11:00 - Coffee Break

11:00 - 12:00 - EBF Feedback

- 11:00 - 11:30 - Peter van Amsterdam (Abbott, on behalf of EBF) p. 29
Update on New Organization
- 11:30 - 12:00 - Margarete Brudny-Kloeppel (Bayer Schering Pharma AG, on behalf of EBF) p. 30
Feedback from EBF 2010 Surveys and Activities

12:00 - 13:40 - Biomarkers

- 12:00 - 12:20 - Liesbeth Vereyken (Janssen Research and Development) p. 30
Challenges with Nucleoside Triphosphate Method Development and Analysis during the Life Cycle of a HCV Program
- 12:20 - 12:40 - Mark Spengler (Chimera) p. 31
Using Ligand-Binding Assay Sensitivity for Improved Matrix Tolerance and Related Parameters by Tailored Sample Dilution
- 12:40 - 13:00 - Speaker to be announced
- 13:00 - 13:20 - Jan Mocak (Slovak University of Technology, Bratislava) p. 32
Effective use of Combination of Lung Malignancy Marker
- 13:20 - 13:45 - Panel Discussion

13:45 - 14:00 - Close out Discussion, Ideas for 2011

14:00 - Adjourn